Liver abnormalities in pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a cardiopulmonary disease with high mortality. In recent years, it has been recognized that PAH is a multi-organ system disease, involving the systemic circulation, kidneys, skeletal muscles, and the central nervous system, among others. Right heart failure produces congestive hepatopathy, a disease state that has direct consequences on liver biochemistry, histology, and systemic glucose and lipid metabolism. This article aims to summarize the consequences of congestive hepatopathy with an emphasis on liver biochemistry, histology, and PAH-targeted therapy. Furthermore, PAH-specific changes in glucose and lipid metabolism will be discussed.

Automated summary

PAH is a cardiopulmonary disease with high mortality, affecting multiple organ systems including the liver, histology, and systemic metabolism. Right heart failure can lead to congestive hepatopathy, impacting liver biochemistry, histology, and overall glucose and lipid metabolism. This article focuses on summarizing the consequences of congestive hepatopathy in PAH patients, with an emphasis on liver biochemistry, histology, and targeted therapy. Additionally, it discusses specific changes in glucose and lipid metabolism associated with PAH.